ERBB3 and non-small cell lung carcinoma: In non-small-cell lung carcinoma (NSCLC) cells with mutated EGFR, amplification of the MET oncogene activates prosurvival ErbB3 signaling, which allows escape from tyrosine kinase inhibition [18] (for review, see [19]).